English
Insider transactions
EDGARXilio Therapeutics, Inc.
Transactions reported by directors, officers and 10% owners on SEC Forms 3, 4 and 5, read from each filing’s XML. Codes and their wording are the SEC’s own.
A Form 4 is due within two business days of the transaction, so the most recent trades may not be filed yet.
Window: transactions dated on or after 2025-11-20.
- Open-market purchases (code P)
- 1 transactions, 5,000 shares
- Sum of shares × price per share: 43,950
- Open-market sales (code S)
- 2 transactions, 8,856 shares
- Sum of shares × price per share: 5,696.1792
Totals add the filed transactions listed; they are counts of what was reported, not a measure of direction.
Showing 1–50 of 79
| Date | Reporting owner | Code | Acquired or disposed | Shares | Price per share, as filed | Value (derived) | Shares owned after | Direct or indirect | Rule 10b5-1 box | Notes | Source |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-10-01 Filed 2026-10-02 | Houvras Yariv Officer: CHIEF MEDICAL OFFICER | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 105,000 | 0 | — | 105,000 | Direct (D) | No | F1
| Open filing 0001193125-26-412466 Read from the filing’s XML Dispute this row |
| 2026-06-11 Filed 2026-06-12 | Brennan Aoife Director | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 5,000 | 0 | — | 5,000 | Direct (D) | No | F1
| Open filing 0001193125-26-269395 Read from the filing’s XML Dispute this row |
| 2026-06-11 Filed 2026-06-12 | Bonstein Sara Director | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 5,000 | 0 | — | 5,000 | Direct (D) | No | F1
| Open filing 0001193125-26-269396 Read from the filing’s XML Dispute this row |
| 2026-06-11 Filed 2026-06-12 | Shannon James Samuel Director | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 5,000 | 0 | — | 5,000 | Direct (D) | No | F1
| Open filing 0001193125-26-269400 Read from the filing’s XML Dispute this row |
| 2026-06-11 Filed 2026-06-12 | ROSS ROBERT W. Director | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 5,000 | 0 | — | 5,000 | Direct (D) | No | F1
| Open filing 0001193125-26-269397 Read from the filing’s XML Dispute this row |
| 2026-06-11 Filed 2026-06-12 | Xu Yuan Director | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 5,000 | 0 | — | 5,000 | Direct (D) | No | F1
| Open filing 0001193125-26-269398 Read from the filing’s XML Dispute this row |
| 2026-06-11 Filed 2026-06-12 | Curran Daniel J. Director | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 5,000 | 0 | — | 5,000 | Direct (D) | No | F1
| Open filing 0001193125-26-269401 Read from the filing’s XML Dispute this row |
| 2026-06-11 Filed 2026-06-12 | Bello Akintunde Olatokumbo Director | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 5,000 | 0 | — | 5,000 | Direct (D) | No | F1
| Open filing 0001193125-26-269399 Read from the filing’s XML Dispute this row |
| 2026-04-15 Filed 2026-04-16 | Blanchard Cheryl R Director | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 10,000 | 0 | — | 10,000 | Direct (D) | No | F1
| Open filing 0001193125-26-159316 Read from the filing’s XML Dispute this row |
| 2026-03-26 Filed 2026-03-30 | Shannon James Samuel Director | POpen market or private purchase of non-derivative or derivative security | Acquired (A) | 5,000 | 8.79 | 43,950Derived: shares × price per share. Exact value 43950.00. | 10,000 | Direct (D) | No | F1, F2
| Open filing 0001193125-26-131745 Read from the filing’s XML Dispute this row |
| 2026-02-13 Filed 2026-02-17 | GILEAD SCIENCES, INC. 10% owner | POpen market or private purchase of non-derivative or derivative security | Acquired (A) | 3,739,000 | 0.5349 | 1,999,991.1Derived: shares × price per share. Exact value 1999991.1000. | 40,384,266 | Direct (D) | No | F1
| Open filing 0001123292-26-000187 Read from the filing’s XML Dispute this row |
| 2026-01-02 Filed 2026-01-05 | Brennan Kevin M. Officer: SVP, FINANCE AND ACCOUNTING | SOpen market or private sale of non-derivative or derivative security | Disposed (D) | 1,826 | 0.6432 | 1,174.4832Derived: shares × price per share. Exact value 1174.4832. | 6,371 | Direct (D) | Yes | F2
| Open filing 0001193125-26-002518 Read from the filing’s XML Dispute this row |
| 2026-01-02 Filed 2026-01-05 | Frankenfield Christopher James Officer: Chief Financial Officer | SOpen market or private sale of non-derivative or derivative security | Disposed (D) | 7,030 | 0.6432 | 4,521.696Derived: shares × price per share. Exact value 4521.6960. | 24,766 | Direct (D) | Yes | F2
| Open filing 0001193125-26-002517 Read from the filing’s XML Dispute this row |
| 2026-01-01 Filed 2026-01-05 | Brennan Kevin M. Officer: SVP, FINANCE AND ACCOUNTING | MExercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Acquired (A) | 5,000 | — | — | 8,197 | Direct (D) | Yes | F1
| Open filing 0001193125-26-002518 Read from the filing’s XML Dispute this row |
| 2026-01-01 Filed 2026-01-05 | Brennan Kevin M. Officer: SVP, FINANCE AND ACCOUNTING | MExercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Disposed (D) | 5,000 | 0 | — | 10,000 | Direct (D) | Yes | F1, F6
| Open filing 0001193125-26-002518 Read from the filing’s XML Dispute this row |
| 2026-01-01 Filed 2026-01-05 | Russo Rene Director · Officer: PRESIDENT AND CEO | MExercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Acquired (A) | 44,250 | — | — | 325,422 | Direct (D) | No | F1
| Open filing 0001193125-26-002512 Read from the filing’s XML Dispute this row |
| 2026-01-01 Filed 2026-01-05 | Russo Rene Director · Officer: PRESIDENT AND CEO | MExercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Disposed (D) | 44,250 | 0 | — | 88,500 | Direct (D) | No | F1, F5
| Open filing 0001193125-26-002512 Read from the filing’s XML Dispute this row |
| 2026-01-01 Filed 2026-01-05 | Luptakova Katarina Officer: CHIEF MEDICAL OFFICER | MExercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Acquired (A) | 16,625 | — | — | 33,250 | Direct (D) | No | F1
| Open filing 0001193125-26-002520 Read from the filing’s XML Dispute this row |
| 2026-01-01 Filed 2026-01-05 | Luptakova Katarina Officer: CHIEF MEDICAL OFFICER | MExercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Disposed (D) | 16,625 | 0 | — | 33,250 | Direct (D) | No | F1, F5
| Open filing 0001193125-26-002520 Read from the filing’s XML Dispute this row |
| 2026-01-01 Filed 2026-01-05 | Frankenfield Christopher James Officer: Chief Financial Officer | MExercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Acquired (A) | 19,375 | — | — | 31,796 | Direct (D) | Yes | F1
| Open filing 0001193125-26-002517 Read from the filing’s XML Dispute this row |
| 2026-01-01 Filed 2026-01-05 | Frankenfield Christopher James Officer: Chief Financial Officer | MExercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Disposed (D) | 19,375 | 0 | — | 38,750 | Direct (D) | Yes | F1, F6
| Open filing 0001193125-26-002517 Read from the filing’s XML Dispute this row |
| 2025-12-31 Filed 2026-01-05 | Brennan Kevin M. Officer: SVP, FINANCE AND ACCOUNTING | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 95,221 | 0 | — | 95,221 | Direct (D) | Yes | F3, F4, F5
| Open filing 0001193125-26-002518 Read from the filing’s XML Dispute this row |
| 2025-12-31 Filed 2026-01-05 | Russo Rene Director · Officer: PRESIDENT AND CEO | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 1,500,258 | 0 | — | 1,500,258 | Direct (D) | No | F2, F3, F4
| Open filing 0001193125-26-002512 Read from the filing’s XML Dispute this row |
| 2025-12-31 Filed 2026-01-05 | Luptakova Katarina Officer: CHIEF MEDICAL OFFICER | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 451,885 | 0 | — | 451,885 | Direct (D) | No | F2, F3, F4
| Open filing 0001193125-26-002520 Read from the filing’s XML Dispute this row |
| 2025-12-31 Filed 2026-01-05 | Frankenfield Christopher James Officer: Chief Financial Officer | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 668,789 | 0 | — | 668,789 | Direct (D) | Yes | F3, F4, F5
| Open filing 0001193125-26-002517 Read from the filing’s XML Dispute this row |
| 2025-11-26 Filed 2025-12-01 | GILEAD SCIENCES, INC. 10% owner | XExercise of in-the-money or at-the-money derivative security | Acquired (A) | 13,335,000 | 0.7499 | 9,999,916.5Derived: shares × price per share. Exact value 9999916.5000. | 36,645,266 | Direct (D) | No | F1, F2
| Open filing 0001123292-25-000675 Read from the filing’s XML Dispute this row |
| 2025-11-26 Filed 2025-12-01 | GILEAD SCIENCES, INC. 10% owner | XExercise of in-the-money or at-the-money derivative security | Disposed (D) | 13,335,000 | 0 | — | 0 | Direct (D) | No | F1, F3, F4
| Open filing 0001123292-25-000675 Read from the filing’s XML Dispute this row |
| 2025-11-21 Filed 2025-11-25 | Luptakova Katarina Officer: CHIEF MEDICAL OFFICER | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 625,000 | 0 | — | 625,000 | Direct (D) | No | F1, F2
| Open filing 0001193125-25-297205 Read from the filing’s XML Dispute this row |
| 2025-11-21 Filed 2025-11-25 | Luptakova Katarina Officer: CHIEF MEDICAL OFFICER | DDisposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | Disposed (D) | 44,210 | — | — | 0 | Direct (D) | No | F4, F3
| Open filing 0001193125-25-297205 Read from the filing’s XML Dispute this row |
| 2025-11-21 Filed 2025-11-25 | Luptakova Katarina Officer: CHIEF MEDICAL OFFICER | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 44,210 | — | — | 44,210 | Direct (D) | No | F4, F3
| Open filing 0001193125-25-297205 Read from the filing’s XML Dispute this row |
| 2025-11-21 Filed 2025-11-25 | Luptakova Katarina Officer: CHIEF MEDICAL OFFICER | DDisposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | Disposed (D) | 15,000 | — | — | 0 | Direct (D) | No | F4, F5
| Open filing 0001193125-25-297205 Read from the filing’s XML Dispute this row |
| 2025-11-21 Filed 2025-11-25 | Luptakova Katarina Officer: CHIEF MEDICAL OFFICER | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 15,000 | — | — | 15,000 | Direct (D) | No | F4, F5
| Open filing 0001193125-25-297205 Read from the filing’s XML Dispute this row |
| 2025-11-21 Filed 2025-11-25 | Luptakova Katarina Officer: CHIEF MEDICAL OFFICER | DDisposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | Disposed (D) | 35,000 | — | — | 0 | Direct (D) | No | F4, F6
| Open filing 0001193125-25-297205 Read from the filing’s XML Dispute this row |
| 2025-11-21 Filed 2025-11-25 | Luptakova Katarina Officer: CHIEF MEDICAL OFFICER | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 35,000 | — | — | 35,000 | Direct (D) | No | F4, F6
| Open filing 0001193125-25-297205 Read from the filing’s XML Dispute this row |
| 2025-11-21 Filed 2025-11-25 | Luptakova Katarina Officer: CHIEF MEDICAL OFFICER | DDisposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | Disposed (D) | 25,000 | — | — | 0 | Direct (D) | No | F4, F7
| Open filing 0001193125-25-297205 Read from the filing’s XML Dispute this row |
| 2025-11-21 Filed 2025-11-25 | Luptakova Katarina Officer: CHIEF MEDICAL OFFICER | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 25,000 | — | — | 25,000 | Direct (D) | No | F4, F7
| Open filing 0001193125-25-297205 Read from the filing’s XML Dispute this row |
| 2025-11-21 Filed 2025-11-25 | Luptakova Katarina Officer: CHIEF MEDICAL OFFICER | DDisposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | Disposed (D) | 106,000 | — | — | 0 | Direct (D) | No | F4, F8
| Open filing 0001193125-25-297205 Read from the filing’s XML Dispute this row |
| 2025-11-21 Filed 2025-11-25 | Luptakova Katarina Officer: CHIEF MEDICAL OFFICER | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 106,000 | — | — | 106,000 | Direct (D) | No | F4, F8
| Open filing 0001193125-25-297205 Read from the filing’s XML Dispute this row |
| 2025-11-21 Filed 2025-11-25 | Brennan Kevin M. Officer: SVP, FINANCE AND ACCOUNTING | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 131,700 | 0 | — | 131,700 | Direct (D) | No | F1, F2
| Open filing 0001193125-25-297207 Read from the filing’s XML Dispute this row |
| 2025-11-21 Filed 2025-11-25 | Brennan Kevin M. Officer: SVP, FINANCE AND ACCOUNTING | DDisposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | Disposed (D) | 55,000 | — | — | 0 | Direct (D) | No | F4, F3
| Open filing 0001193125-25-297207 Read from the filing’s XML Dispute this row |
| 2025-11-21 Filed 2025-11-25 | Brennan Kevin M. Officer: SVP, FINANCE AND ACCOUNTING | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 55,000 | — | — | 55,000 | Direct (D) | No | F4, F3
| Open filing 0001193125-25-297207 Read from the filing’s XML Dispute this row |
| 2025-11-21 Filed 2025-11-25 | Brennan Kevin M. Officer: SVP, FINANCE AND ACCOUNTING | DDisposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | Disposed (D) | 25,000 | — | — | 0 | Direct (D) | No | F4, F5
| Open filing 0001193125-25-297207 Read from the filing’s XML Dispute this row |
| 2025-11-21 Filed 2025-11-25 | Brennan Kevin M. Officer: SVP, FINANCE AND ACCOUNTING | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 25,000 | — | — | 25,000 | Direct (D) | No | F4, F5
| Open filing 0001193125-25-297207 Read from the filing’s XML Dispute this row |
| 2025-11-21 Filed 2025-11-25 | Brennan Kevin M. Officer: SVP, FINANCE AND ACCOUNTING | DDisposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | Disposed (D) | 20,000 | — | — | 0 | Direct (D) | No | F4, F6
| Open filing 0001193125-25-297207 Read from the filing’s XML Dispute this row |
| 2025-11-21 Filed 2025-11-25 | Brennan Kevin M. Officer: SVP, FINANCE AND ACCOUNTING | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 20,000 | — | — | 20,000 | Direct (D) | No | F4, F6
| Open filing 0001193125-25-297207 Read from the filing’s XML Dispute this row |
| 2025-11-21 Filed 2025-11-25 | Russo Rene Director · Officer: PRESIDENT AND CEO | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 2,075,000 | 0 | — | 2,075,000 | Direct (D) | No | F1, F2
| Open filing 0001193125-25-297203 Read from the filing’s XML Dispute this row |
| 2025-11-21 Filed 2025-11-25 | Russo Rene Director · Officer: PRESIDENT AND CEO | DDisposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | Disposed (D) | 239,703 | — | — | 0 | Direct (D) | No | F4, F3
| Open filing 0001193125-25-297203 Read from the filing’s XML Dispute this row |
| 2025-11-21 Filed 2025-11-25 | Russo Rene Director · Officer: PRESIDENT AND CEO | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 239,703 | — | — | 239,703 | Direct (D) | No | F4, F3
| Open filing 0001193125-25-297203 Read from the filing’s XML Dispute this row |
| 2025-11-21 Filed 2025-11-25 | Russo Rene Director · Officer: PRESIDENT AND CEO | DDisposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | Disposed (D) | 473,334 | — | — | 0 | Direct (D) | No | F4, F3
| Open filing 0001193125-25-297203 Read from the filing’s XML Dispute this row |
| 2025-11-21 Filed 2025-11-25 | Russo Rene Director · Officer: PRESIDENT AND CEO | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 473,334 | — | — | 473,334 | Direct (D) | No | F4, F3
| Open filing 0001193125-25-297203 Read from the filing’s XML Dispute this row |
Institutional holders (Form 13F)
Quarter ending 2026-09-30: 8,925 filings read, the latest filed 2026-11-19. Prior quarter ending 2026-06-30: 9,176 filings read.
Showing 1–30 of 30
| Manager | Shares or principal | Value as filed | Change from the prior quarter | Source |
|---|---|---|---|---|
| Bain Capital Life Sciences Investors, LLC | 664,021 SH | 6,009,390 dollars | Unchanged Prior quarter: 664,021 | Open filing 0001193125-26-462089 Filed 2026-11-16 Dispute this row |
| GILEAD SCIENCES, INC. | 650,389 SH | 5,886,020 dollars | Unchanged Prior quarter: 650,389 | Open filing 0001123292-26-001479 Filed 2026-11-06 Dispute this row |
| ORBIMED ADVISORS LLC | 592,300 SH | 5,360,315 dollars | Unchanged Prior quarter: 592,300 | Open filing 0001172661-26-005349 Filed 2026-11-16 Dispute this row |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 464,598 SH | 4,204,612 dollars | Higher by 353,057 Prior quarter: 111,541 | Open filing 0001172661-26-005200 Filed 2026-11-16 Dispute this row |
| Frazier Life Sciences Management, L.P. | 422,505 SH | 3,823,670 dollars | Unchanged Prior quarter: 422,505 | Open filing 0001892134-26-000007 Filed 2026-11-16 Dispute this row |
| VANGUARD CAPITAL MANAGEMENT LLC | 198,181 SH | 1,793,538 dollars | Higher by 19,664 Prior quarter: 178,517 | Open filing 0002100119-26-001711 Filed 2026-11-13 Dispute this row |
| Stonepine Capital Management, LLC | 189,092 SH | 1,711,283 dollars | Lower by 36,902 Prior quarter: 225,994 | Open filing 0001440771-26-000027 Filed 2026-11-13 Dispute this row |
| Sio Capital Management, LLC | 152,464 SH | 1,379,799 dollars | Unchanged Prior quarter: 152,464 | Open filing 0001214659-26-014302 Filed 2026-11-16 Dispute this row |
| Merck Co., Inc. | 105,982 SH | 959,137 dollars | Unchanged Prior quarter: 105,982 | Open filing 0000310158-26-000249 Filed 2026-11-13 Dispute this row |
| RENAISSANCE TECHNOLOGIES LLC Partly reported under another manager | 63,553 SH | 575,155 dollars | Lower by 600 Prior quarter: 64,153 | Open filing 0001037389-26-000062 Filed 2026-11-12 Dispute this row |
| MORGAN STANLEY Partly reported under another manager | 53,674 SH | 485,750 dollars | Lower by 3,280 Prior quarter: 56,954 | Open filing 0000895421-26-000309 Filed 2026-11-13 Dispute this row |
| GEODE CAPITAL MANAGEMENT, LLC Partly reported under another manager | 41,449 SH | 375,140 dollars | Higher by 2,394 Prior quarter: 39,055 | Open filing 0001214717-26-000012 Filed 2026-11-06 Dispute this row |
| TWO SIGMA INVESTMENTS, LP | 40,104 SH | 362,941 dollars | Higher by 25,560 Prior quarter: 14,544 | Open filing 0000899140-26-001341 Filed 2026-11-16 Dispute this row |
| VANGUARD FIDUCIARY TRUST CO | 28,193 SH | 255,147 dollars | Higher by 5,599 Prior quarter: 22,594 | Open filing 0000933478-26-000017 Filed 2026-11-13 Dispute this row |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | 17,544 SH | 158,773 dollars | Unchanged Prior quarter: 17,544 | Open filing 0001107261-26-000007 Filed 2026-11-16 Dispute this row |
| GSA CAPITAL PARTNERS LLP | 16,673 SH | 151 dollars | Higher by 3,083 Prior quarter: 13,590 | Open filing 0001362033-26-000013 Filed 2026-11-16 Dispute this row |
| STATE STREET CORP Partly reported under another manager | 13,311 SH | 120,465 dollars | Unchanged Prior quarter: 13,311 | Open filing 0000093751-26-000747 Filed 2026-11-12 Dispute this row |
| PRUDENTIAL FINANCIAL INC Partly reported under another manager | 13,180 SH | 119,279 dollars | Not in the prior quarter’s filings read | Open filing 0001137774-26-000233 Filed 2026-11-16 Dispute this row |
| HRT FINANCIAL LP | 12,453 SH | 112 dollars | Not in the prior quarter’s filings read | Open filing 0001475597-26-000249 Filed 2026-11-13 Dispute this row |
| NORTHERN TRUST CORP Partly reported under another manager | 11,650 SH | 105,433 dollars | Not in the prior quarter’s filings read | Open filing 0000073124-26-000067 Filed 2026-11-16 Dispute this row |
| CITADEL ADVISORS LLC Partly reported under another manager | 11,061 SH | 100,102 dollars | Lower by 14,889 Prior quarter: 25,950 | Open filing 0001104659-26-128228 Filed 2026-11-16 Dispute this row |
| BlackRock, Inc. Partly reported under another manager | 10,908 SH | 98,718 dollars | Higher by 2,151 Prior quarter: 8,757 | Open filing 0002012383-26-003985 Filed 2026-11-13 Dispute this row |
| Vanguard Global Advisers, LLC | 3,359 SH | 30,399 dollars | Not in the prior quarter’s filings read | Open filing 0001811242-26-000017 Filed 2026-11-13 Dispute this row |
| Steward Partners Investment Advisory, LLC | 714 SH | 6,462 dollars | Unchanged Prior quarter: 714 | Open filing 0001723397-26-000006 Filed 2026-11-13 Dispute this row |
| UBS Group AG Partly reported under another manager | 544 SH | 4,924 dollars | Higher by 530 Prior quarter: 14 | Open filing 0001610520-26-000121 Filed 2026-11-10 Dispute this row |
| ROYAL BANK OF CANADA Partly reported under another manager | 98 SH | 1,000 dollars | Not in the prior quarter’s filings read | Open filing 0001140361-26-044123 Filed 2026-11-16 Dispute this row |
| Tower Research Capital LLC (TRC) Partly reported under another manager | 94 SH | 851 dollars | Not in the prior quarter’s filings read | Open filing 0001533421-26-000010 Filed 2026-11-16 Dispute this row |
| Key Financial Inc | 59 SH | 534 dollars | Unchanged Prior quarter: 59 | Open filing 0001420506-26-002442 Filed 2026-11-02 Dispute this row |
| JONES FINANCIAL COMPANIES LLLP Partly reported under another manager | 58 SH | 524 dollars | Higher by 29 Prior quarter: 29 | Open filing 0001193125-26-459442 Filed 2026-11-13 Dispute this row |
| CITIGROUP INC Partly reported under another manager | 1 SH | 9 dollars | Not in the prior quarter’s filings read | Open filing 0000831001-26-000052 Filed 2026-11-04 Dispute this row |
Managers in the prior quarter with no filing read for the latest
They may simply not have filed yet: absent from the latest quarter’s filings read is not the same as a position sold.
- Velan Capital Investment Management LP 14,285 SH
- PRELUDE CAPITAL MANAGEMENT, LLC 11,600 SH
- SECURITY NATIONAL BANK OF SIOUX CITY IOWA /IA/ 321 SH
- BARCLAYS PLC 115 SH
- Form 13F covers long positions in Section 13(f) securities only: no short positions and no securities outside that list.
- Reports for quarters ending before 2013-06-30 were filed as plain text and are not read.
- A manager that has not yet filed for the latest quarter is absent, not at zero; filings are due up to 45 days after quarter end.
- A change is the difference between two quarter-end snapshots, not a trade.
- A position reported under another manager may also appear in that manager’s filing; rows are not added together.
- Holdings the securities list cannot place with this company, or places ambiguously, are not shown.
Trades by members of Congress
Periodic transaction reports filed by U.S. House members that name this company’s stock. Dates and amounts are as filed.
No House member’s trade in this company is placed in the store. A trade not yet filed or not linked to a company is absent, not zero.
5% holders (Schedule 13D and 13G)
Schedules filed in the SEC’s structured format (late 2024 onward) are read here. Earlier schedules are free text and are not read.
| Holder | Percent of class | Shares held | Event date | Form | Source |
|---|---|---|---|---|---|
| Coastlands Capital LP Common Stock, par value $0.0001 per share | 9.99 | 731,573.00 | 09/30/2026 Filed 2026-11-13 | SCHEDULE 13G/AAmendment 1 | Open filing 0001104659-26-127419 Dispute this row |
| Coastlands Capital Partners LP Common Stock, par value $0.0001 per share | 9.99 | 731,573.00 | 09/30/2026 Filed 2026-11-13 | SCHEDULE 13G/AAmendment 1 | Open filing 0001104659-26-127419 Dispute this row |
| Coastlands Capital GP LLC Common Stock, par value $0.0001 per share | 9.99 | 731,573.00 | 09/30/2026 Filed 2026-11-13 | SCHEDULE 13G/AAmendment 1 | Open filing 0001104659-26-127419 Dispute this row |
| Coastlands Capital LLC Common Stock, par value $0.0001 per share | 9.99 | 731,573.00 | 09/30/2026 Filed 2026-11-13 | SCHEDULE 13G/AAmendment 1 | Open filing 0001104659-26-127419 Dispute this row |
| Matthew D. Perry Common Stock, par value $0.0001 per share | 9.99 | 731,573.00 | 09/30/2026 Filed 2026-11-13 | SCHEDULE 13G/AAmendment 1 | Open filing 0001104659-26-127419 Dispute this row |
| Adage Capital Management, L.P. Common Stock, par value $0.0001 per share | 7.06 | 464,598.00 | 09/30/2026 Filed 2026-11-12 | SCHEDULE 13G | Open filing 0000919574-26-007551 Dispute this row |
| Robert Atchinson Common Stock, par value $0.0001 per share | 7.06 | 464,598.00 | 09/30/2026 Filed 2026-11-12 | SCHEDULE 13G | Open filing 0000919574-26-007551 Dispute this row |
| Phillip Gross Common Stock, par value $0.0001 per share | 7.06 | 464,598.00 | 09/30/2026 Filed 2026-11-12 | SCHEDULE 13G | Open filing 0000919574-26-007551 Dispute this row |
| StemPoint Capital LP Common stock, par value $0.0001 per share | 9.5 | 628,866.00 | 06/30/2026 Filed 2026-08-14 | SCHEDULE 13G/AAmendment 2 | Open filing 0001104659-26-096755 Dispute this row |
| StemPoint Capital Management GP LLC Common stock, par value $0.0001 per share | 9.5 | 628,866.00 | 06/30/2026 Filed 2026-08-14 | SCHEDULE 13G/AAmendment 2 | Open filing 0001104659-26-096755 Dispute this row |
| Michelle Ross Common stock, par value $0.0001 per share | 9.5 | 628,866.00 | 06/30/2026 Filed 2026-08-14 | SCHEDULE 13G/AAmendment 2 | Open filing 0001104659-26-096755 Dispute this row |
| Point72 Asset Management, L.P. Common Stock, par value $0.0001 per share | 0 | 0.00 | 03/31/2026 Filed 2026-05-15 | SCHEDULE 13G/AAmendment 2 | Open filing 0000919574-26-003488 Dispute this row |
| Point72 Capital Advisors, Inc. Common Stock, par value $0.0001 per share | 0 | 0.00 | 03/31/2026 Filed 2026-05-15 | SCHEDULE 13G/AAmendment 2 | Open filing 0000919574-26-003488 Dispute this row |
| Steven A. Cohen Common Stock, par value $0.0001 per share | 0 | 0.00 | 03/31/2026 Filed 2026-05-15 | SCHEDULE 13G/AAmendment 2 | Open filing 0000919574-26-003488 Dispute this row |
| Sirenia Capital Management LP Common Stock, par value $0.0001 per share | 9.9 | 1,142,862.00 | 03/31/2026 Filed 2026-05-15 | SCHEDULE 13G | Open filing 0000919574-26-003213 Dispute this row |
| Alex Silverstein Common Stock, par value $0.0001 per share | 9.9 | 1,142,862.00 | 03/31/2026 Filed 2026-05-15 | SCHEDULE 13G | Open filing 0000919574-26-003213 Dispute this row |
| BCLS II Equity Opportunities, LP Common Stock, par value $0.0001 per share | 9.99 | 664,021 | 03/31/2026 Filed 2026-05-15 | SCHEDULE 13G/AAmendment 4 | Open filing 0001193125-26-226925 Dispute this row |
| Bain Capital Life Sciences Fund II, L.P. Common Stock, par value $0.0001 per share | 0 | 0 | 03/31/2026 Filed 2026-05-15 | SCHEDULE 13G/AAmendment 4 | Open filing 0001193125-26-226925 Dispute this row |
| BCIP Life Sciences Associates, LP Common Stock, par value $0.0001 per share | 0 | 0 | 03/31/2026 Filed 2026-05-15 | SCHEDULE 13G/AAmendment 4 | Open filing 0001193125-26-226925 Dispute this row |
| ORBIMED ADVISORS LLC Common Stock, par value $0.0001 per share | 9.99 | 642,000.00 | 03/31/2026 Filed 2026-05-15 | SCHEDULE 13G | Open filing 0000947871-26-000552 Dispute this row |
| OrbiMed Capital GP X LLC Common Stock, par value $0.0001 per share | 7.49 | 481,500.00 | 03/31/2026 Filed 2026-05-15 | SCHEDULE 13G | Open filing 0000947871-26-000552 Dispute this row |
| Bain Capital Life Sciences Fund II, L.P. Common Stock, par value $0.0001 per share | 1.3 | 992,111 | 12/31/2025 Filed 2026-02-17 | SCHEDULE 13G/AAmendment 3 | Open filing 0001193125-26-054804 Dispute this row |
| BCIP Life Sciences Associates, LP Common Stock, par value $0.0001 per share | 0.2 | 120,833 | 12/31/2025 Filed 2026-02-17 | SCHEDULE 13G/AAmendment 3 | Open filing 0001193125-26-054804 Dispute this row |
| BCLS II Equity Opportunities, LP Common Stock, par value $0.0001 per share | 8.5 | 6,259,742 | 12/31/2025 Filed 2026-02-17 | SCHEDULE 13G/AAmendment 3 | Open filing 0001193125-26-054804 Dispute this row |
| BCLS II Investco, LP Common Stock, par value $0.0001 per share | 0 | 0 | 12/31/2025 Filed 2026-02-17 | SCHEDULE 13G/AAmendment 3 | Open filing 0001193125-26-054804 Dispute this row |
| StemPoint Capital LP Common stock, par value $0.0001 per share | 8.4 | 6,030,028.00 | 12/31/2025 Filed 2026-02-17 | SCHEDULE 13G/AAmendment 1 | Open filing 0001104659-26-015985 Dispute this row |
| StemPoint Capital Management GP LLC Common stock, par value $0.0001 per share | 8.4 | 6,030,028.00 | 12/31/2025 Filed 2026-02-17 | SCHEDULE 13G/AAmendment 1 | Open filing 0001104659-26-015985 Dispute this row |
| Michelle Ross Common stock, par value $0.0001 per share | 8.4 | 6,030,028.00 | 12/31/2025 Filed 2026-02-17 | SCHEDULE 13G/AAmendment 1 | Open filing 0001104659-26-015985 Dispute this row |
| Frazier Life Sciences Public Fund, L.P. Common Stock, par value $0.0001 per share | 6.7 | 4,676,472.00 | 12/31/2025 Filed 2026-02-13 | SCHEDULE 13G/AAmendment 2 | Open filing 0001231919-26-000149 Dispute this row |
| FHMLSP, L.P. Common Stock, par value $0.0001 per share | 6.7 | 4,676,472.00 | 12/31/2025 Filed 2026-02-13 | SCHEDULE 13G/AAmendment 2 | Open filing 0001231919-26-000149 Dispute this row |
| FHMLSP, L.L.C. Common Stock, par value $0.0001 per share | 6.7 | 4,676,472.00 | 12/31/2025 Filed 2026-02-13 | SCHEDULE 13G/AAmendment 2 | Open filing 0001231919-26-000149 Dispute this row |
| Frazier Life Sciences X, L.P. Common Stock, par value $0.0001 per share | 0.2 | 149,060.00 | 12/31/2025 Filed 2026-02-13 | SCHEDULE 13G/AAmendment 2 | Open filing 0001231919-26-000149 Dispute this row |
| FHMLS X, L.P. Common Stock, par value $0.0001 per share | 0.2 | 149,060.00 | 12/31/2025 Filed 2026-02-13 | SCHEDULE 13G/AAmendment 2 | Open filing 0001231919-26-000149 Dispute this row |
| FHMLS X, L.L.C. Common Stock, par value $0.0001 per share | 0.2 | 149,060.00 | 12/31/2025 Filed 2026-02-13 | SCHEDULE 13G/AAmendment 2 | Open filing 0001231919-26-000149 Dispute this row |
| Frazier Life Sciences XI, L.P. Common Stock, par value $0.0001 per share | 0.6 | 396,902.00 | 12/31/2025 Filed 2026-02-13 | SCHEDULE 13G/AAmendment 2 | Open filing 0001231919-26-000149 Dispute this row |
| FHMLS XI, L.P. Common Stock, par value $0.0001 per share | 0.6 | 396,902.00 | 12/31/2025 Filed 2026-02-13 | SCHEDULE 13G/AAmendment 2 | Open filing 0001231919-26-000149 Dispute this row |
| FHMLS XI, L.L.C. Common Stock, par value $0.0001 per share | 0.6 | 396,902.00 | 12/31/2025 Filed 2026-02-13 | SCHEDULE 13G/AAmendment 2 | Open filing 0001231919-26-000149 Dispute this row |
| Frazier Life Sciences XII, L.P. Common Stock, par value $0.0001 per share | 1.0 | 692,657.00 | 12/31/2025 Filed 2026-02-13 | SCHEDULE 13G/AAmendment 2 | Open filing 0001231919-26-000149 Dispute this row |
| FHMLS XII, L.P. Common Stock, par value $0.0001 per share | 1.0 | 692,657.00 | 12/31/2025 Filed 2026-02-13 | SCHEDULE 13G/AAmendment 2 | Open filing 0001231919-26-000149 Dispute this row |
| FHMLS XII, L.L.C. Common Stock, par value $0.0001 per share | 1.0 | 692,657.00 | 12/31/2025 Filed 2026-02-13 | SCHEDULE 13G/AAmendment 2 | Open filing 0001231919-26-000149 Dispute this row |
| James N. Topper Common Stock, par value $0.0001 per share | 0.2 | 149,060.00 | 12/31/2025 Filed 2026-02-13 | SCHEDULE 13G/AAmendment 2 | Open filing 0001231919-26-000149 Dispute this row |
| Patrick J. Heron Common Stock, par value $0.0001 per share | 0.2 | 149,060.00 | 12/31/2025 Filed 2026-02-13 | SCHEDULE 13G/AAmendment 2 | Open filing 0001231919-26-000149 Dispute this row |
| GILEAD SCIENCES, INC. Common Stock, par value $0.0001 per share | 19.9 | 14,517,678 | 12/31/2025 Filed 2026-02-12 | SCHEDULE 13G/AAmendment 3 | Open filing 0001123292-26-000166 Dispute this row |
| Coastlands Capital LP Common Stock, par value $0.0001 per share | 9.99 | 5,346,069.00 | 12/04/2025 Filed 2025-12-11 | SCHEDULE 13G | Open filing 0001104659-25-120365 Dispute this row |
| Coastlands Capital Partners LP Common Stock, par value $0.0001 per share | 9.99 | 5,346,069.00 | 12/04/2025 Filed 2025-12-11 | SCHEDULE 13G | Open filing 0001104659-25-120365 Dispute this row |
| Coastlands Capital GP LLC Common Stock, par value $0.0001 per share | 9.99 | 5,346,069.00 | 12/04/2025 Filed 2025-12-11 | SCHEDULE 13G | Open filing 0001104659-25-120365 Dispute this row |
| Coastlands Capital LLC Common Stock, par value $0.0001 per share | 9.99 | 5,346,069.00 | 12/04/2025 Filed 2025-12-11 | SCHEDULE 13G | Open filing 0001104659-25-120365 Dispute this row |
| Matthew D. Perry Common Stock, par value $0.0001 per share | 9.99 | 5,346,069.00 | 12/04/2025 Filed 2025-12-11 | SCHEDULE 13G | Open filing 0001104659-25-120365 Dispute this row |
| ADAR1 Capital Management, LLC Common Stock, par value $0.0001 per share | 9.3 | 381,000.00 | 09/30/2025 Filed 2026-11-16 | SCHEDULE 13G | Open filing 0001104659-26-128741 Dispute this row |
| Daniel Schneeberger Common Stock, par value $0.0001 per share | 9.3 | 381,000.00 | 09/30/2025 Filed 2026-11-16 | SCHEDULE 13G | Open filing 0001104659-26-128741 Dispute this row |
Percent is of the class the filing names, as the holder stated it. Members of a group each report the group’s shares, so rows are not added together.
What was read
2,660,713 filings read, dated 2004-06-14 to 2026-11-19: Forms 3, 3/A, 4, 4/A, 5, 5/A.
Years can be incomplete while the archive is still being read. A year with few filings here is not a statement that few were made.
| Filing year | Filings read |
|---|---|
| 2015 | 77,800 |
| 2016 | 222,642 |
| 2017 | 222,009 |
| 2018 | 223,345 |
| 2019 | 216,482 |
| 2020 | 226,343 |
| 2021 | 249,835 |
| 2022 | 231,682 |
| 2023 | 229,674 |
| 2024 | 234,045 |
| 2025 | 235,520 |
| 2026 | 263,123 |
Filings made before the SEC required XML are listed, not extracted.